2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
|
|
- Brendan Haynes
- 5 years ago
- Views:
Transcription
1 2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations
2 Harguneet Singh Science Internship Program: Applied Medicine
3 Comparisons of Outcomes among Patients Treated with Brachytherapy, External Beam Radiation or Radical Prostatectomy for High Risk Prostate Cancer Harguneet Singh Jay Ciezki, MD Chandana Reddy, MS
4 Abstract Study was focused on patients with high risk prostate cancer. Patients were treated with brachytherapy, external beam radiation or radical prostatectomy. Outcomes of treatments were compared. Most outcomes were similar among the modalities.
5 Introduction Prostate - A gland within the male reproductive system that is located just below the bladder, whose main function is to secrete a fluid that nourishes and protects the sperm. Prostate Cancer - a malignant growth of the glandular cells within the prostate. 2 nd leading cause of cancer death in American men
6 Background Prostate-Specific Antigen (PSA) Biopsy Gleason Score Clinical Staging To be considered at high risk: One high risk factor: Clinical stage T3 Biopsy Gleason score 8-10 PSA > 20 ng/ml Or two intermediate risk factors: Clinical stage T2b or T2c PSA >10 ng/ml Biopsy Gleason score 7
7 Background (cont.) Treatment options: Brachytherapy (BT) internal radiation with seeds External Beam Radiation (EBRT) machine directs x-ray beams at tumor Radical Prostatectomy (RP) surgical removal of prostate
8 Hypothesis High-risk patients who were treated with brachytherapy, external beam radiation or radical prostatectomy will have comparable rates of biochemical control, clinical control, and cause-specific survival.
9 Methodology Inception Cohort Study Study population: 2736 high risk prostate cancer patients Treated at the Cleveland Clinic from 1996 to 2012 Data was extracted from patients electronic medical records and entered into an IRB approved database. Some additional factors that were examined: Use of neoadjuvant therapy (hormonal treatment given before primary treatment) Frequency of post treatment PSA testing
10 Methodology (cont.) Biochemical failure Radical Prostatectomy post treatment PSA 0.4 ng/ml Radiation therapy post treatment PSA value 2 ng/ml above PSA nadir (lowest) value Clinical failures Local failure recurrence of cancer within prostate or prostate bed Distant failure cancer metastasizes to another site within the body (ex. bone or lymph nodes) Cause Specific Survival Death from prostate cancer
11 Data: Patient Disease and Treatment Characteristics All Patients External Beam Radiation Brachytherapy Radical Prostatectomy Number of Patients Risk Two Intermediate Factors n % n % n % n % High T1T2A Clinical Stage T2BC T < < Initial PSA (ng/ml) 10-< Unknown Biopsy Gleason Score
12 Data: Patient Disease and Treatment Characteristics All Patients External Beam Radiation Brachytherapy Radical Prostatectomy Neoadjuvant Therapy n % n % n % n % N Y UNK Duration of Androgen Deprivation (months) 2 Post Treatment PSAs Biochemical Failure Clinical Failure Local Failure Distant Failure > UNK N Y N Y N Y N Y N Y
13 Data: Patient Disease and Treatment Characteristics All Patients External Beam Radiation Brachytherapy Radical Prostatectomy n % n % n % n % Alive Status Died from Prostate Cancer Age (years) Initial PSA (ng/ml) # of Post Treatment PSAs PSA Follow Up (months) # of PSAs per Year Follow Up Time (months) Died from Other Diseases Median Range Median Range Median Range Median Range Median Range Median Range
14 Results: Biochemical Relapse Free Survival Multivariable Analysis for Biochemical Failure EBRT External Beam Radiation BT Brachytherapy RP Radical Prostatectomy Treatment Clinical Stage Variable P-Value Hazard Ratio 95%CI L 95%CI U BT vs RP BT vs EBRT RP vs EBRT T2BC vs T1T2A T3 vs T1T2A T3 vs T2BC Biopsy 7 vs Gleason 8-10 vs Score 8-10 vs 7 < Initial PSA < Duration of NeoAdj Tx (m) PSA Frequency < PSA Frequency*Time < Kaplan Meier Curve
15 Results: Clinical Relapse Free Survival Multivariable Analysis for Clinical Failure Treatment Clinical Stage Biopsy Gleason Score Variable P-Value Hazard Ratio 95%CI L 95%CI U BT vs RP BT vs EBRT RP vs EBRT T2BC vs T1T2A T3 vs T1T2A < T3 vs T2BC vs vs 6 < vs 7 < Initial PSA Duration of NeoAdj Tx (m) PSA Frequency < PSA Frequency*Time <
16 Results: Cause Specific Mortality Multivariable Analysis for Cause Specific Mortality Treatme nt Clinical Stage Biopsy Gleason Score Variable P-Value Hazard Ratio 95%CI L 95%CI U BT vs RP BT vs EBRT RP vs EBRT T2BC vs T1T2A T3 vs T1T2A T3 vs T2BC vs vs 6 < vs 7 < Initial PSA Duration of NeoAdj Tx (m) Age <
17 Conclusions Radical prostatectomy Worse biochemical control Best clinical control and better cause specific survival Better salvage therapy options External beam radiation Worse clinical control and cause specific survival Were higher risk and had longer follow up Brachytherapy: Had biochemical and clinical control comparable to EBRT Better cause specific survival Smallest sample size
18 Recommendations Limitations: Limited follow-up information on some patients Patients were not randomized to treatment option. Recommendations: Consider patient s health Consider side effects Patient s preference
19 References "Adjuvant and Neoadjuvant Therapy for Breast Cancer." National Cancer Institute. N.p., n.d. Web. 24 July Marks, Sheldon. Prostate & Cancer: A Family Guide to Diagnosis, Treatment & Survival. Tucson, AZ: Fisher, Print. "NCCN Guidelines for Patients Prostate Cancer." NCCN Guidelines for Patients. N.p., n.d. Web. 24 July "Prostate." MedicineNet. N.p., n.d. Web. 24 July "What Are the Key Statistics about Prostate Cancer?" What Are the Key Statistics about Prostate Cancer? N.p., n.d. Web. 24 July "What Is Brachytherapy?" Cancer Treatment Centers of America: Brachytherapy.com. N.p., n.d. Web. 24 July 2015.
20 Special Thanks Jay Ciezki, MD Chandana Reddy, MS Department of Radiation Oncology Glickman Urological and Kidney Institute Bryan Pflaum, MFA Nedra Starling, MA, MPH, ABD/DrPH Office of Government and Community Relations Civic Education Department
21 Copyright 2015 Cleveland Clinic Foundation
Best Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationClinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer
Original Article Radiat Oncol J 205;33():2-28 http://dx.doi.org/0.3857/roj.205.33..2 pissn 2234-900 eissn 2234-356 Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationIrreversible Electroporation for the Treatment of Recurrent Prostate Cancer
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More informationDoes RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia
Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia Disclosures Advisory Board/honoraria: Varian Advisory Board: Breast
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationScreening and Diagnosis Prostate Cancer
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More information2016 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2016 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Nadia Paskert Science Internship Program: Applied Medicine Breast Reconstruction
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationDate Modified: March 31, Clinical Quality Measures for PQRS
Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process
More informationA comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer
ORIGINAL RESEARCH A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer Daniel Taussky, MD; 1 Véronique Ouellet, MD; 2 Guila Delouya,
More informationDate Modified: May 29, Clinical Quality Measures for PQRS
Date Modified: May 29, 2014 Clinical Quality s for PQRS # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3
More informationPROSTATE CANCER CONTENT CREATED BY. Learn more at
PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation
More informationPROSTATE CANCER (PCa)
PROSTATE CANCER (PCa) Tomasz Drewa Department of Urology, Collegium Medicum, UMK ? PCa = 11/6/16 PCa Urology, 1995 11/6/16 PSA increase Natural history of prostate cancer patient Testosterone Deprywacja
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationTanaka et al. BMC Cancer (2017) 17:573 DOI /s
Tanaka et al. BMC Cancer (2017) 17:573 DOI 10.1186/s12885-017-3565-1 RESEARCH ARTICLE Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationThe Selenium and Vitamin E Prevention Trial
The largest-ever-prostate cancer prevention trial is now underway. The study will include a total of 32,400 men and is sponsored by the National Cancer Institute and a network of researchers known as the
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationProstate Cancer UK s Best Practice Pathway
Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationBiochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy
Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir October 2015, Volume: 7, Issue: 6, Pages: 1330-1335, DOI: 10.14661/1330 Biochemical progression-free survival in localized prostate cancer
More informationRadical Prostatectomy:
Overtreatment and undertreatment Radical Prostatectomy: An Emerging Standard of Care for High Risk Prostate Cancer Matthew R. Cooperberg, MD,MPH UCSF Radiation Oncology Update San Francisco, CA April 2,
More informationSupported by M. D. Anderson Cancer Center physician investigator funds. We thank Gerald E. Hanks, MD, for help and guidance with this project.
1496 Biochemical and Clinical Significance of the Posttreatment Prostate-Specific Antigen Bounce for Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone A Multiinstitutional Pooled
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationCAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy
Original research CAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy Michel Zimmermann, MD; 1 Guila Delouya, MD, MSc; 1,2 Abdullah M. Alenizi, MD;
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More information2014 myresearch SCIENCE Internship Program
2014 myresearch SCIENCE Internship Program Maya Gaines-Smith Science Internship Program Does Mobilization of Patients With a Cancer Diagnosis Decrease Pain? Maya Gaines-Smith Marianne Douglas, MS CCC/SLP
More informationMeasuring the value of healthcare activities. Susan Rollason, Director of Finance and Strategy
Measuring the value of healthcare activities Susan Rollason, Director of Finance and Strategy Items covered What are we doing and why? What have we done so far? What challenges have we faced? What are
More informationGene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.
SUPPLEMENTARY DATA Gene expression profiling predicts clinical outcome of prostate cancer Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M. Hoffman, William L. Gerald Table of Contents
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationPrognostic Factors for Overall Survival and Risk Stratification of Prostate Cancer Patients with Biochemical Failure
Western University Scholarship@Western Electronic Thesis and Dissertation Repository September 2015 Prognostic Factors for Overall Survival and Risk Stratification of Prostate Cancer Patients with Biochemical
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationMedication Prior Authorization Form
Policy Number: 1047 Eligard (leuprolide acetate) 7.5mg Eligard (leuprolide acetate) 22.5mg Eligard (leuprolide acetate) 30mg Eligard (leuprolide acetate)45mg Firmagon (degarelix) Lupaneta Pack (leuprolide
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationIntensity Modulated Radiotherapy (IMRT) of the Prostate
Medical Policy Manual Medicine, Policy No. 137 Intensity Modulated Radiotherapy (IMRT) of the Prostate Next Review: August 2018 Last Review: November 2017 Effective: December 1, 2017 IMPORTANT REMINDER
More informationDate of preparation- January 2018 Janssen Biotech, Inc /18 em Reporter s guide to. prostate cancer
Date of preparation- January 2018 Janssen Biotech, Inc. 2018 02/18 em-01856 Reporter s guide to prostate cancer What is the prostate? The prostate is a gland located below the bladder, wrapped around the
More informationAFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options
AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although
More information2011 PROSTATE BRACHYTHERAPY STUDY
20 PROSTATE BRACHYTHERAPY STUDY CRITERIA Patients receiving prostate brachytherapy at Cox from 2002-200. In this study, we will look at patients with the following prognostic features: PSA
More informationActive surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation
Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Alice Dragomir, PhD Fabio Cury, MD Armen Aprikian, MD Introduction Clinical and economic burden
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationAttachment #2 Overview of Follow-up
Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationProstatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
More informationStereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience.
Stereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience. Elisabetta Ponti MD, Gianluca Ingrosso MD, Alessandra Carosi PhD, Luana
More informationS Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet
S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationChristine M. Fisher, MD
Prostate biopsy upgrading and its implications on treatment modality and outcomes in men treated with radical prostatectomy or permanent seed implantation at UT M.D. Anderson Cancer Center, 2000-2001 By
More informationSalvage Cryotherapy. Bernard Malavaud MD, PhD, FEBU Institut Universitaire du Cancer Toulouse (France)
Urethra protection Argon decompression -40 /-60 C 17G hollow needles Salvage Cryotherapy Ice all TRUS positioning & monitoring temperature monitoring of the rectal wall ernard Malavaud MD, PhD, FEU Institut
More information